Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China

Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China

Background: CYP2C19 loss-of-function (LOF) alleles reduce the effectiveness of clopidogrel in patients undergoing percutaneous coronary intervention for acute coronary syndrome. However, the clinical impact of implementing CYP2C19 gene-guided pharmacotherapy is unclear, especially among the Chinese...

Full description

Bibliographic Details
Main Authors: Yi Zhang, Xiu-Jin Shi, Wen-Xing Peng, Jia-Lun Han, Bai-Di Lin, Ru Zhang, Yun-Nan Zhang, Jia-Lin Yan, Juan-Juan Wei, Yi-Fan Wang, Su-Wei Chen, Nan Nan, Zhen-Wei Fang, Yong Zeng, Yang Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Pharmacology
Subjects:
CYP2C19
clopidogrel
ticagrelor
acute coronary syndrome
gene-guided antiplatelet therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.582929/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.582929/full

Similar Items